Why the study?
Patients with arterial hypertension are at increased risk for severe COVID-19, prompting evaluation of underlying pathogenetic mechanisms involving the RAAS and the impact of RAAS inhibitors.
Does the use of ACE inhibitors / ARBs improve survival in patients with arterial hypertension and COVID-19?
Does the use of ACE inhibitors / ARBs improve survival in patients with arterial hypertension and COVID-19?
The use of ACE inhibitors and ARBs in patients with COVID-19 and arterial hypertension is associated with lower mortality, supporting their continued use during infection.
Supports continued ACEi/ARB use in AH with COVID-19; leaves open causal confirmation by RCTs.
A review of current publications suggests that patients with arterial hypertension (AH) are at increased risk for severe course and fatal outcome of COVID-19. The main pathogenetic mechanisms explaining the association of AH with COVID-19 include the effect of coronavirus on the functioning of the renin-angiotensin-aldosterone system (RAAS), which is involved in the development and progression of AH. The review presents the results of a number of studies evaluating the effect of the use of ACE inhibitors / ARBs on the development and course of COVID-19 in patients with cardiovascular diseases. The results of international data analysis showed that the use of ACE inhibitors / ARBs in patients with AH and COVID-19 is associated with lower rates of total mortality, and the use of ACE inhibitors, statins and the female sex are associated with a greater likelihood of patient survival. The data on the promising development of new drugs affecting the functioning of RAAS are presented.
No takes yet. Share an insight, caveat, or question.
Yakubava et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: